TIGIT免疫检查点阻断恢复CD8+ T细胞对多发性骨髓瘤的免疫
研究探讨TIGIT阻断对多发性骨髓瘤(MM)的治疗潜力。小鼠和人类MM进展均与CD8+ T细胞TIGIT高表达相关,TIGIT+ CD8+ T细胞呈功能障碍表型。TIGIT缺陷小鼠肿瘤负荷降低、生存延长;抗TIGIT单抗增强患者CD8+ T细胞效应功能并抑制MM发展。
要点
- MM进展与CD8+ T细胞TIGIT高表达相关,TIGIT+ CD8+ T细胞增殖减少、细胞因子产生障碍。
- TIGIT缺陷小鼠接种Vk*MYC MM细胞后血清单克隆免疫球蛋白降低、肿瘤负荷减少、生存延长。
- 抗TIGIT单抗增强MM患者CD8+ T细胞效应功能并抑制MM发展。
核心结论
- 数据表明TIGIT在MM中具有免疫抑制作用,支持开发TIGIT阻断策略治疗MM患者。
研究设计与样本
- 研究在小鼠和人类中观察MM进展与CD8+ T细胞TIGIT表达的关系。
- 使用Vk*MYC小鼠MM细胞攻击TIGIT缺陷小鼠。
- 使用单克隆抗体阻断TIGIT,检测MM患者CD8+ T细胞效应功能及MM发展。
主要发现
- 小鼠和人类MM进展均与CD8+ T细胞高表达TIGIT相关。
- MM患者TIGIT+ CD8+ T细胞增殖减少,对抗CD3/CD28/CD2或骨髓瘤抗原刺激不能产生细胞因子。
- TIGIT缺陷小鼠接种Vk*MYC MM细胞后血清单克隆免疫球蛋白水平降低,伴肿瘤负荷减少和生存延长。
- 抗TIGIT单抗增加MM患者CD8+ T细胞效应功能并抑制MM发展。
临床怎么用
- 原文结论支持开发TIGIT阻断策略用于治疗MM患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM domains (TIGIT) is another immune checkpoint receptor known to negatively regulate T-cell functions. In this study, we investigated the therapeutic potential of TIGIT blockade to unleash immune responses against MM. We observed that, in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD8+ T cells. TIGIT+ CD8+ T cells from MM patients exhibited a dysfunctional phenotype characterized by decreased proliferation and inability to produce cytokines in response to anti-CD3/CD28/CD2 or myeloma antigen stimulation. Moreover, when challenged with Vk*MYC mouse MM cells, TIGIT-deficient mice showed decreased serum monoclonal immunoglobulin protein levels associated with reduced tumor burden and prolonged survival, indicating that TIGIT limits antimyeloma immune responses. Importantly, blocking TIGIT using monoclonal antibodies increased the effector function of MM patient CD8+ T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.
引用
- Guillerey C, Harjunpää H, Carrié N, et al. TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood. 2018. PMID: 29986909. doi:10.1182/blood-2018-01-825265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。